Literature DB >> 2897836

Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia.

H Szechtman1, C Nahmias, E S Garnett, G Firnau, G M Brown, R D Kaplan, J M Cleghorn.   

Abstract

This study examines whether the duration of treatment with antipsychotic drugs influences the regional distribution of cerebral [18F]2-fluoro-2-deoxy-D-glucose utilization as measured by positron emission tomography. Two groups of schizophrenic patients are compared with normal volunteers (n = 10). One group (n = 5) consisted of patients treated for one year, and the second (n = 12) of patients medicated for four to 14 years (mean +/- SD duration, 7.4 +/- 3.4 years). The first group was also examined before patients received their first dose ever of antipsychotic medication. One year of medication was not sufficient to alter the schizophrenic profile of cerebral cortical glucose activity but did elevate activity of the corpus striatum. Medication for 7.4 years also did not alter the schizophrenic pattern of frontal hyperactivity and posterior hypoactivity, although deviations from control values appeared less marked than after one year. On the other hand, in patients medicated for 7.4 years, there was perhaps an even greater increase in the activity of the corpus striatum and of the thalamus. Thus, duration of exposure to antipsychotic medication may affect the pattern of cerebral glucose activity; possibly, even longer exposure may contribute to the hypofrontality noted by others, although this can be confounded with the duration of illness as a factor. In considering the biological significance of the observed profile of cortical glucose activity, we introduce the concept of cerebral metabolic tone. We suggest that a disturbance of this tonus may account for some symptoms of schizophrenia and could be consistent with the hypothesis of abnormal developmental changes in the brains of schizophrenics.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2897836     DOI: 10.1001/archpsyc.1988.01800300019002

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  17 in total

Review 1.  Functional brain mapping of psychopathology.

Authors:  G D Honey; P C Fletcher; E T Bullmore
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-04       Impact factor: 10.154

2.  Functional neuroimaging in mental disorders.

Authors:  Philip K McGuire; Kazunori Matsumoto
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

Review 3.  Testing models of thalamic dysfunction in schizophrenia using neuroimaging.

Authors:  K Sim; T Cullen; D Ongur; S Heckers
Journal:  J Neural Transm (Vienna)       Date:  2005-10-27       Impact factor: 3.575

4.  Maternal influenza viral infection causes schizophrenia-like alterations of 5-HT₂A and mGlu₂ receptors in the adult offspring.

Authors:  José L Moreno; Mitsumasa Kurita; Terrell Holloway; Javier López; Richard Cadagan; Luis Martínez-Sobrido; Adolfo García-Sastre; Javier González-Maeso
Journal:  J Neurosci       Date:  2011-02-02       Impact factor: 6.167

Review 5.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

6.  The fallacy of the medical model and the dangers of psychotropic drugs as a mode of treatment for mental disorders.

Authors:  V D Sanua
Journal:  J Prim Prev       Date:  1996-09

7.  Hypermetabolic pattern in frontal cortex and other brain regions in unmedicated schizophrenia patients. Results from a FDG-PET study.

Authors:  M Soyka; W Koch; H J Möller; T Rüther; K Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-04-18       Impact factor: 5.270

8.  Diminished cerebral metabolic response to motor stimulation in schizophrenics: a PET study.

Authors:  W Guenther; J D Brodie; E J Bartlett; S L Dewey; F A Henn; N D Volkow; K Alper; A Wolkin; R Cancro; A P Wolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1994       Impact factor: 5.270

9.  Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

Authors:  C J Bench; A A Lammertsma; R J Dolan; P M Grasby; S J Warrington; K Gunn; M Cuddigan; D J Turton; S Osman; R S Frackowiak
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

10.  Regional brain metabolism in schizophrenia: An FDG-PET study.

Authors:  R Seethalakshmi; S R Parkar; N Nair; S A Adarkar; A G Pandit; S A Batra; N S Baghel; S H Moghe
Journal:  Indian J Psychiatry       Date:  2006-07       Impact factor: 1.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.